NM_020919.4:c.*1004G>A

Variant summary

Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1

The NM_020919.4(ALS2):​c.*1004G>A variant causes a 3 prime UTR change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0791 in 152,374 control chromosomes in the GnomAD database, including 567 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.

Frequency

Genomes: 𝑓 0.079 ( 567 hom., cov: 32)
Exomes 𝑓: 0.064 ( 0 hom. )

Consequence

ALS2
NM_020919.4 3_prime_UTR

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:3

Conservation

PhyloP100: 0.808

Publications

11 publications found
Variant links:
Genes affected
ALS2 (HGNC:443): (alsin Rho guanine nucleotide exchange factor ALS2) The protein encoded by this gene contains an ATS1/RCC1-like domain, a RhoGEF domain, and a vacuolar protein sorting 9 (VPS9) domain, all of which are guanine-nucleotide exchange factors that activate members of the Ras superfamily of GTPases. The protein functions as a guanine nucleotide exchange factor for the small GTPase RAB5. The protein localizes with RAB5 on early endosomal compartments, and functions as a modulator for endosomal dynamics. Mutations in this gene result in several forms of juvenile lateral sclerosis and infantile-onset ascending spastic paralysis. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2008]
ALS2 Gene-Disease associations (from GenCC):
  • ALS2-related motor neuron disease
    Inheritance: AR Classification: DEFINITIVE Submitted by: ClinGen
  • amyotrophic lateral sclerosis type 2, juvenile
    Inheritance: AR Classification: STRONG Submitted by: Genomics England PanelApp
  • infantile-onset ascending hereditary spastic paralysis
    Inheritance: AR Classification: STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), Genomics England PanelApp, Orphanet
  • juvenile primary lateral sclerosis
    Inheritance: AR Classification: STRONG, SUPPORTIVE Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae), Orphanet
  • juvenile amyotrophic lateral sclerosis
    Inheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -12 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.82).
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.226 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
ALS2NM_020919.4 linkc.*1004G>A 3_prime_UTR_variant Exon 34 of 34 ENST00000264276.11 NP_065970.2 Q96Q42-1A8K4R4

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
ALS2ENST00000264276.11 linkc.*1004G>A 3_prime_UTR_variant Exon 34 of 34 1 NM_020919.4 ENSP00000264276.6 Q96Q42-1

Frequencies

GnomAD3 genomes
AF:
0.0792
AC:
12040
AN:
152082
Hom.:
566
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0430
Gnomad AMI
AF:
0.172
Gnomad AMR
AF:
0.0500
Gnomad ASJ
AF:
0.0700
Gnomad EAS
AF:
0.237
Gnomad SAS
AF:
0.112
Gnomad FIN
AF:
0.105
Gnomad MID
AF:
0.111
Gnomad NFE
AF:
0.0886
Gnomad OTH
AF:
0.0732
GnomAD4 exome
AF:
0.0640
AC:
11
AN:
172
Hom.:
0
Cov.:
0
AF XY:
0.0789
AC XY:
9
AN XY:
114
show subpopulations
African (AFR)
AC:
0
AN:
0
American (AMR)
AC:
0
AN:
0
Ashkenazi Jewish (ASJ)
AC:
0
AN:
0
East Asian (EAS)
AC:
0
AN:
0
South Asian (SAS)
AC:
0
AN:
0
European-Finnish (FIN)
AF:
0.0655
AC:
11
AN:
168
Middle Eastern (MID)
AC:
0
AN:
0
European-Non Finnish (NFE)
AF:
0.00
AC:
0
AN:
4
Other (OTH)
AC:
0
AN:
0
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.502
Heterozygous variant carriers
0
1
1
2
2
3
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
GnomAD4 genome
AF:
0.0791
AC:
12046
AN:
152202
Hom.:
567
Cov.:
32
AF XY:
0.0816
AC XY:
6073
AN XY:
74420
show subpopulations
African (AFR)
AF:
0.0432
AC:
1794
AN:
41542
American (AMR)
AF:
0.0499
AC:
763
AN:
15286
Ashkenazi Jewish (ASJ)
AF:
0.0700
AC:
243
AN:
3472
East Asian (EAS)
AF:
0.237
AC:
1228
AN:
5186
South Asian (SAS)
AF:
0.112
AC:
542
AN:
4824
European-Finnish (FIN)
AF:
0.105
AC:
1108
AN:
10588
Middle Eastern (MID)
AF:
0.109
AC:
32
AN:
294
European-Non Finnish (NFE)
AF:
0.0886
AC:
6026
AN:
67986
Other (OTH)
AF:
0.0724
AC:
153
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.500
Heterozygous variant carriers
0
561
1121
1682
2242
2803
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
148
296
444
592
740
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0837
Hom.:
1639
Bravo
AF:
0.0739
Asia WGS
AF:
0.165
AC:
574
AN:
3476

ClinVar

Significance: Benign
Submissions summary: Benign:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Amyotrophic lateral sclerosis type 2, juvenile Benign:1
Jan 12, 2018
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

ALS2-related disorder Benign:1
Jan 12, 2018
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

not provided Benign:1
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.82
CADD
Benign
9.5
DANN
Benign
0.40
PhyloP100
0.81
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs11300; hg19: chr2-202565570; API